Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936207 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL1224329 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6935578 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6936201 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6150895 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL633484 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6866936 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL4648170 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL6866940 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL5176774 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912458-B1 | NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECTS AT RISK OF PRETERM DELIVERY | NYU WINTHROP HOSPITAL (US) | 2018-07-18 | — | — | EP | claimed |
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | SHIONOGI & CO., LTD. (JP) | 2005-10-06 | — | — | US | claimed |
| EP-1535629-A1 | DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME | Japan Science and Technology Agency (JP) | 2005-06-01 | — | — | EP | claimed |
| EP-2912458-B1 | NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECTS AT RISK OF PRETERM DELIVERY | NYU WINTHROP HOSPITAL (US) | 2018-07-18 | — | — | EP | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| US-8568967-B2 | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| US-8334294-B2 | 4,8-diphenyl-polyazanaphthalene derivatives | ALMIRALL, S.A. (ES) | 2012-12-18 | — | — | US | disclosed |
| US-20120225904-A1 | New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives | ALMIRALL, S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| US-8258122-B2 | 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives | ALMIRALL, S.A. (ES) | 2012-09-04 | — | — | US | disclosed |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | ARIMURA AKINORI (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1193243-A1 | NOVEL PROCESS FOR PRODUCING BICYCLIC AMINO ALCOHOL | SHIONOGI & CO., LTD. (JP) | 2002-04-03 | — | — | EP | disclosed |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HONMA TSUNETOSHI (JP) | 2002-02-28 | — | — | US | disclosed |
| US-6346628-B1 | REACTING 4-MERCAPTOPHENOL WITH A PROPARYGL GOUP AND PROTECTION OF HYDROXYL GROUP, OXIDIZING THE PRODUCT, AND THERMAL REARRANGEMENT TO CYCLIZE, FOLLOWED BY FURTHER OXIDATION | SHIONOGI & CO., LTD. (JP) | 2002-02-12 | — | — | US | disclosed |
| US-20020016476-A1 | PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | HONMA TSUNETOSHI (JP) | 2002-02-07 | — | — | US | disclosed |
| US-6320060-B1 | INTRODUCING PROPARGYL GROUP INTO 4-MERCAPTOPHENOL, PROTECTING HYDROXYL GROUP, OXIDIZING COMPOUND, SUBJECTING TO THERMAL REARRANGEMENT REACTION, SUBJECTING TO STEPWISE OXIDATION OF HYDROXYMETHYL GROUP AND OPTIONALLY DEPROTECTION | SHIONOGI & CO., LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-1084711-A1 | REMEDIES FOR ITCHING CONTAINING PGD 2? ANTAGONISTS | SHIONOGI & CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-1069122-A1 | PROCESS FOR PRODUCING 5-HYDROXYBENZO b]THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-6083974-A | BENZOTHIOPHENECARBOXAMIDE CONTAINING NORPINANE RING IS USEFUL FOR PREVENTING NASAL BLOCKAGE | SHIONOGI & CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016476-A1 | PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | HPD, PTGDR2, PTGS2 | PTGDR 4/4885TBXA2R 27/4885 |
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | HPGDS, PTGDR, PTGDR2 | PTGDR 2/4885TBXA2R 34/4885 |
| US-20120225904-A1 | New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives | MAPK7, MAPK1, MAP3K7 | PTGDR 731/4885TBXA2R 765/4885 |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HPD, PTGDR2, PTGS2 | PTGDR 4/4885TBXA2R 27/4885 |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | PTGDR 4/4885TBXA2R 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.